Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) announced that CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference.

The on-demand webcast will be available via the Investors section of Voyager’s website starting 7:00 a.m. ET on June 15, 2026, and will be archived for at least 30 days.

News Market Reaction – VYGR

+1.16%

+1.16% Session close to close

In the Jun 12 session, VYGR gained 1.16%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights management’s participation in a neuro-focused conference, extending Voy...

Analysis

This announcement highlights management’s participation in a neuro-focused conference, extending Voyager’s visibility as it advances VY1706 and other neurology programs. Recent updates showed FDA IND clearance, cash of $171.7M funding operations into 2028, and a $400,000,000 mixed shelf plus increased authorized shares that expand financing flexibility. Investors may watch how upcoming clinical milestones, capital-raising decisions, and further scientific presentations interact with this broader strategic positioning.

Key Figures

Cash balance: $171.7M Net loss: $27.9M Collaboration revenue: $2.6M +5 more

8 metrics

Cash balance $171.7M Cash, cash equivalents and marketable securities at 03/31/2026

Net loss $27.9M Net loss for Q1 2026

Collaboration revenue $2.6M Collaboration revenue in Q1 2026 (primarily Neurocrine and Novartis)

Authorized capital stock 245,000,000 shares Total authorized capital stock after June 9, 2026 charter amendment

Authorized common stock 240,000,000 shares Authorized common shares after June 9, 2026 charter amendment

Shelf registration size $400,000,000 Maximum aggregate offering amount under mixed shelf registration

ATM program size $100,000,000 At-the-market common stock program under shelf with TD Securities

Armistice stake 3,500,000 shares (5.87%) Beneficial ownership per Schedule 13G/A filing

Historical Context

5 past events · Latest: Jun 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 01	IND clearance	Positive	-2.1%	FDA cleared IND for VY1706 Alzheimer’s gene therapy trial initiation.
May 13	Clinical data update	Positive	+0.0%	GLP tox showed VY1706 well tolerated with up to 64% tau reduction.
May 07	Quarterly earnings	Neutral	+2.3%	Q1 2026 results with $171.7M cash and outlined 2026 milestones.
Apr 27	Conference presentations	Positive	+0.3%	ASGCT presentations spotlighted VY1706 and TRACER capsid innovations.
Mar 09	Full-year results	Positive	+21.6%	Full-year 2025 update with $201.7M cash and 2026 clinical catalysts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive clinical and regulatory updates have often seen generally aligned or muted price reactions, with one notable divergence on FDA IND clearance.

Recent Company History

Over the past six months, Voyager has highlighted advancing neurology programs and strengthening its balance sheet. FDA IND clearance for VY1706 and supportive GLP toxicology data have positioned the tau gene therapy for first-in-human dosing in H2 2026. Q1 2026 results showed collaboration revenue of $2.6M, a net loss of $27.9M, and cash of $171.7M funding operations into 2028. Earlier, full-year 2025 results noted $201.7M cash and key 2026 catalysts, framing today’s conference appearance within an ongoing execution narrative.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference.

An on-demand webcast of the pre-recorded fireside chat will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com starting at 7:00 a.m. ET on June 15, 2026. The on-demand webcast will be archived on the Company’s website for at least 30 days.

About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit http://www.voyagertherapeutics.com.

Voyager Therapeutics^® is a registered trademark, and TRACER™ and Voyager NeuroShuttle™ are trademarks, of Voyager Therapeutics, Inc.

Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Sarah McCabe, sarah.mccabe@altasum.com
Media: Lisa Guiterman, voyagerpr@scientpr.com

FAQ

When will Voyager Therapeutics' (VYGR) fireside chat be available from the H.C. Wainwright 7th Annual Neuro Perspectives Conference?

The Voyager Therapeutics fireside chat will be available on-demand starting at 7:00 a.m. ET on June 15, 2026. According to Voyager, investors can access it through the company’s Investors website section.

How can investors watch Voyager Therapeutics' (VYGR) webcast from the H.C. Wainwright Neuro Perspectives Hybrid Conference?

Investors can watch the webcast on-demand via the Investors section of Voyager Therapeutics’ website. According to Voyager, the pre-recorded fireside chat will be accessible beginning June 15, 2026.

Who will represent Voyager Therapeutics (VYGR) at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference?

Voyager Therapeutics will be represented by Alfred W. Sandrock, Jr., M.D., Ph.D., its Chief Executive Officer. According to Voyager, he will participate in a pre-recorded fireside chat webcast for investors.

Will Voyager Therapeutics' (VYGR) H.C. Wainwright conference webcast be available after June 15, 2026?

Yes, the webcast will be archived on Voyager Therapeutics’ website for at least 30 days. According to Voyager, investors can access the replay through the Investors section during this period.

What type of event is Voyager Therapeutics (VYGR) hosting at the H.C. Wainwright Neuro Perspectives Conference?

Voyager Therapeutics is hosting a pre-recorded fireside chat as part of the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. According to Voyager, the discussion will be available via on-demand webcast for investors.